A new social media campaign called #ThinkHand aims to challenge perceptions about what is important for multiple sclerosis patients - and also bring about changes in drug trials.
The trial of Sangamo’s gene-editing treatment for a rare and debilitating disease has got off to a good start, with no safety concerns reported so far.
Accusations from President Trump that the UK’s National Health Service is hugely unpopular and “going broke and not working” has earned him a sharp rebuke from politicians and the public.
The MHRA's chief executive accompanied the Prime Minister to Beijing this week, and signed a new memorandum of understanding (MoU) with Chinese counterparts.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.